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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYFLT3 and c-KITare crucial regulators of hematopoietic stem and progenitor cells.We investigated the role of STS1 and STS2 on FLT3 and c-
KIT phosphorylation, activity, and function in normal and stress-induced hematopoiesis. STS1/STS2-deficient mice show a profound
expansion of multipotent progenitor and lymphoid primed multipotent progenitor cells with elevated colony-forming capacity.
Although long-term hematopoietic stem cells are not increased in numbers, lack of STS1 and STS2 significantly promotes long-term re-
population activity, demonstrating a pivotal role of STS1/STS2 in regulating hematopoietic stem and progenitor cell fitness. Biochemical
analysis identified STS1/STS2 as direct phosphatases of FLT3 and c-KIT. Loss of STS1/STS2 induces hyperphosphorylation of FLT3, en-
hances AKT signaling, and confers a strong proliferative advantage. Therefore, our study reveals that STS1 and STS2 may serve as novel
pharmaceutical targets to improve hematopoietic recovery after bone marrow transplantation.INTRODUCTION
Hematopoietic stem cells (HSCs) are capable of both self-
renewal and production of mature blood lineages. Players
in this balanced regulation include transcription factors,
cell-cycle regulators, signalingmolecules, surface receptors,
and cytokines (Rossi et al., 2012). The type III receptor tyro-
sine kinases (RTKs), which include FMS-like tyrosine ki-
nase-3 (FLT3), c-KIT (referred to hereafter as KIT), cFMS,
and PDGFR play a key role in normal andmalignant hema-
topoiesis. Importantly, FLT3 and KIT are highly expressed
on hematopoietic stem and progenitor cells (HSPCs)
(Adolfsson et al., 2005; Boyer et al., 2011; Buza-Vidas
et al., 2009) as well as on the surface of leukemic blasts in
most patients with acute myeloid leukemia (Sargin et al.,
2007; Toffalini and Demoulin, 2010).
Extracellular binding of a specific ligand to its respective
RTK induces dimerization and autophosphorylation on
specific tyrosine residues, followed by activation of intra-
cellular signaling cascades. The amplitude and duration of
RTK signaling is tightly controlled by receptor ubiquitina-
tion, internalization, and degradation, resulting in signal
termination (Verstraete and Savvides, 2012). In this
context, E3 ligases mediate ubiquitination, thereby initi-
ating internalization and endocytosis (Ryan et al., 2006;
Toffalini and Demoulin, 2010; Verstraete and Savvides,
2012). Dephosphorylation of RTKs by phosphatases has
been less studied so far and appears to be a transient andStem Cellfine-tuned negative regulation of RTK signaling (Dikic
and Giordano, 2003; Sastry and Elferink, 2011).
We have reported previously that the E3 ligase CBL binds
to autophosphorylated FLT3 and KITand leads to FLT3 and
KIT ubiquitination via its E3 ligase activity (Bandi et al.,
2009; Sargin et al., 2007). It has been shown that FLT3
signaling is greatly amplified in FLT3+ multipotent progen-
itors (MPPs) in a genetic mouse model expressing a RING
fingermutant of CBL, leading to amyeloid proliferative dis-
ease. This pheonotype was reversible by treatment with the
FLT3 kinase inhibitor AC220 (Rathinam et al., 2010; Taylor
et al., 2012). Here we analyze the function of two known
binding partners of CBL and evaluate their potential phos-
phatase activity toward FLT3 and KIT: STS1 and STS2 (sup-
pressor of T cell receptor signaling 1 and 2, also known as
TULA2 and TULA and UBASH3B and UBASH3A, respec-
tively). STS1 and STS2 proteins share a 75% amino acid ho-
mology and are characterized by a ubiquitin binding
domain (UBA), a SH3 domain, and a phosphoglycerate
mutase-like domain (PGM) (Carpino et al., 2002, 2004).
Both proteins bind CBL through their SH3 domain and
regulate interactions between trafficking receptors and
the ubiquitin sorting machinery in the endosome through
their UBA domain (Kowanetz et al., 2004; Mikhailik et al.,
2007; Raguz et al., 2007). STS1/STS2 have been shown to
constitutively interact with CBL and inhibit CBL-mediated
degradation of the epidermal growth factor (EGF) receptor
(Feshchenko et al., 2004; Raguz et al., 2007). Importantly,Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors 633
Figure 1. Loss of STS1/STS2 Leads to Expansion of MPP and LMPP Cell Populations
(A) Representative FACS staining plots showing LSK (LinSCA+KIT+) compartment distribution (left) and HSC (LSKFLT3CD34), MPP
(LSKFLT3CD34+), LMPP (LSKFLT3+CD34+) distribution (right) in 4-month-old mice.
(B) Quantification of LSK cell frequency (top) and absolute numbers in double tibias and temurs (bottom) in 4-month-old mice (n = 3).
(C) Representative FACS staining plots (top) and percentage of FLT3+ cells within lineage-negative (Lin), LinSCA+, or LSK compartments
(bottom) in 4-month-old mice (n = 3).
(D) Representative FACS staining plots and quantification of CD150 and CD48 staining populations within the LSK compartment in
9-month-old mice (n = 5).
(legend continued on next page)
634 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors
STS1 has been shown to be a tyrosine phosphatase for the
EGF and PDGF receptors, with the PGM domain encoding
the phosphatase activity (Hoeller et al., 2006; Mikhailik
et al., 2007). Interestingly, the phosphatase activity of
STS2 is much weaker, although the PGM domains of STS1
and STS2 are highly homologous (Carpino et al., 2009;
Chen et al., 2009a, 2009b). Single STS1 or STS2 knockout
mice are viable, develop normally, and do not display any
obvious abnormalities, and no differences were detected
concerning bone marrow cellularity, B and T cell develop-
ment, or proliferative capacity. Mice lacking both STS pro-
teins are shown to be hyper-responsive to T cell receptor
stimulation, resulting in an increase in both cytokine pro-
duction and susceptibility to autoimmunity (Carpino et al.,
2002, 2004).
The effect of STS1/STS2 on FLT3 and KIT and the func-
tional consequences for hematopoiesis are unknown. By
combining the genetic STS1/STS2 knockout mouse model
with appropriate biochemical tools, we have analyzed the
effect of STS1 and STS2 on HSPCs and FLT3/KIT-dependent
signaling.RESULTS
Loss of STS1 and STS2 Leads to a Phenotypic
Expansion of the MPP and Lymphoid-Primed MPP
Cell Populations
Defined hematopoietic compartments were separated, by
fluorescence-activated cell sorting (FACS), from the bone
marrow (BM) of wild-type (WT) C57BL/6 mice and
analyzed by real-time PCR, demonstrating that Sts1 and
Sts2 mRNA was expressed in HSPCs (Figure S1A).
The hematopoietic compartments of STS1/ and
STS2/ knockout (STS1KO and STS2KO) mice as well as
of STS1//STS2/ double knockout (dKO) mice under-
went detailed phenotypic characterization. However,
FACS analysis revealed a remarkable relative and absolute
increase in LinSCA+KIT+ (LSK) cells in the bone marrow
of dKO mice (Figures 1A, 1B, and 1E). This difference was
already significant in 4-month-old mice (Figure 1B) and
enhanced further with age in 12- to 14-month-old mice
(Figure 1E). Notably, the increased LSK population in
dKO mice is attributable to MPPs (LSK FLT3CD34+) and
FLT3+MPP/lymphoid-primed MPPs (LMPPs) (LSK FLT3+
CD34+) (Figures 1B and 1E), which are considered to be
multipotent progenitor cells with limited or no self-
renewal activity (Adolfsson et al., 2005; Yamamoto et al.,(E) Representative FACS staining plots (top) and quantification of LSK
(n = 4).
(F) Representative FACS staining plots showing CLP (LinKITintSCAint
cation of CLP cell frequency (right) in 6-month-old mice (WT and dK
(B–F) Data represent mean ± SEM. *p < 0.05; **p < 0.01; n.s., not si
Stem Cell2013). In contrast, we found no significant difference in
the HSC (LSK FLT3CD34) compartment (Figures 1B
and 1E). This phenotype appears to be largely due to the
loss of STS1 (Figure 1E) but not STS2 (Figures S1BS1E).
However, STS1 KO cells appear to have a more variable
phenotype (i.e., larger error bars; Figure 1E) compared
with dKO cells.
Importantly, although there was only aminor gain in the
mean surface expression intensity (data not shown), the
relative frequency of FLT3+ bone marrow cells was
increased greatly in dKO mice within LSK cells compared
with the WT (Figure 1C) and, to a lesser degree, KIT+ as
well (data not shown).
As we postulated that loss of STS1/STS2 affects FLT3 sur-
face expression, we sought for independent markers to sup-
port our findings by using the signaling lymphocyte activa-
tion module (SLAM) markers CD150 and CD48 (Kiel et al.,
2005; Yilmaz et al., 2006). As shown in Figure 1D, left, we
again observed a significant expansion of CD150CD48+
populationat the expenseof theCD150+CD48 cellswithin
LSK population. However, because of the expansion of the
LSK population, no differences in the absolute number or
frequency of HSCs (LSK CD150+CD48) were found in the
bone marrow, whereas MPPs/LMPPs (LSK CD150CD48/+)
were increased greatly in dKO mice (Figure 1D, right).
There was no significant shift of myeloid progenitor
(megakaryocyte-erythroid progenitor [MEP], common
myeloid progenitor [CMP], and granulocyte-macrophage
progenitor [GMP]) populations between WT and dKO
mice (Figure S2A). Furthermore, although lymphoid pro-
genitor populations were largely determined by FLT3
expression (Adolfsson et al., 2005; Karsunky et al., 2008;
Mackarehtschian et al., 1995), the percentage of the com-
mon lymphoid progenitor (CLP, LinCD127+KITintSCAint
FLT3+B220) cell population remained unchanged between
genotypes (Figure 1F). However, as reportedpreviously, dKO
mice display an increased B cell and decreased Tcell popula-
tion in the spleen andperipheral blood (Figure S2B;Carpino
et al., 2004), indicating a skewing within lymphoid cells.
Taken together, depletion of STS1 and STS2 leads to a
phenotypic expansion of the MPP and LMPP populations.Increased Colony-Forming Capacity of dKO Bone
Marrow Cells
Given the phenotypic enrichment of LSK in dKO mice
(Figure 1), we asked whether this leads to functional differ-
ences. In serial colony-forming assays, no differences were, HSC, MPP, and LMPP cell frequency (bottom) in 14-month-old mice
CD127+FLT3+B220) compartment distribution (left) and quantifi-
O, n = 4; STS1KO, n = 3).
gnificant (Student’s t test). See also Figures S1 and S2.
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observed in the initial plating,whereas STS1/STS2-deficient
total bone marrow cells generated significantly more col-
onies from the second replating onward (Figure 2A). Types
of colonies did not differ between genotypes (Figure 2B).
Furthermore, LSK cells from dKO mice not only gave rise
to more colonies (Figure 2C), but, most importantly, these
colonies displayed higher cell numbers (Figure 2D).
Morphological classification of the colonies indicates a
trend toward increased colony-forming unit-granulocyte/
macrophages (CFU-GMs) and decreased CFU-megakaryo-
cytes (CFU-Ms) (Figure 2E). This expansion of cell numbers
wasmostly attributed to the loss of STS1, albeit with higher
variability compared with dKO (Figures 2C and 2D). Sur-
facemarker analysis of these cells revealed an accumulation
of less differentiated cells (defined as MAC-1 KIT+ CD48+
CD16/32; Figure 2F) in dKOmice. No changes were found
in the differentiation markers GR1, MAC-1, CD71, and
CD19 (data not shown). These findings indicate that the
absence of STS1 and STS2 does not significantly alter the
terminal lineage differentiation but, rather, the expansion
of more immature cells.
To confirm the in vitro data, we performed a CFU-S assay
(colony-forming units in spleen) with WT and dKO bone
marrow cells as donors. As shown in Figure 2G, we
observed a significantly increased colony number in dKO
donors, functionally confirming the phenotypically
increased MPP/LMPP populations. Importantly, signifi-
cantly decreased colony growth was demonstrated in
AC220-treated mice. The colony numbers were decreased
significantly in dKO donors and resulted in equal numbers
as WT donors (Figure 2G).
Enhanced Long-Term Repopulation Capacity
of STS1/STS2-Depleted HSCs
To investigate the long-term repopulation capacity of dKO
HSCs, we performed a competitive transplantation experi-
ment, as depicted schematically in Figure 3A. When total
bone marrow cells were used as the donor source, hemato-
poietic repopulation was very similar in dKO and WT cells
until week 8. Thereafter, hematopoiesis derived from dKO
donor mice expanded faster than in WT donor cells (Fig-
ure 3B), which is most likely a reflection of the higher
LSK cell content in dKO mice (Figures 1B and 1E). We
then asked whether the phenotypically increased MPPs/
LMPPs fromdKOmice acquired long-term repopulation ac-
tivity. Therefore, we transplanted the same numbers of
LMPP cells (LSKCD150CD48+) and found a significantly
higher engraftment of cells lacking STS1/STS2 at early
time points (4 weeks) but not at later time points (from
8 weeks onward; Figure 3C). Staining of the lineage marker
showed a strikingly increased T cell population and
decreased B cell population (Figure 3D; Figure S3A). These
data demonstrate, on one hand, that LMPP cells from636 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The AdKO mice have enhanced short-term repopulation ability
because of increased fitness and, on the other hand, that
they exhibit no long-term repopulation capacity.
Next we transplanted sorted LSK cells (which phenotyp-
ically contain equal or less HSCs in dKO because of the
expansion of MPPs/LMPPs) into WT recipient mice. In
the primary recipients, no difference in the engraftment,
expansion, or differentiation of donor cells was found in
the peripheral blood (Figures 3E and 3F; Figure S3B). How-
ever, bonemarrow analysis showed a trend toward a higher
LSK andLSKCD34 cell percentage indKOcells (Figure 3G).
Importantly, when the bone marrow cells from this trans-
plantation were re-transplanted into secondary recipients,
a significantly enhanced engraftment of STS1/STS2-
depleted cells was observed (Figure 3H), with a shift from
T to B cells in dKOmice after 8 weeks after the second trans-
plantation (Figure 3I; Figure S3C). Consistently, LSK cells
(both CD34+ and CD34) from dKO mice were increased
significantly, suggesting a tremendous functional growth
advantage of dKO over WT cells (Figure 3J). Therefore,
although no differences were found in primary recipients
(Figures 3E and 3G), we observed a dramatically enhanced
expansion of dKO donor cells in the spleens and bone
marrow of secondary recipient mice (Figures 3K and 3L,
respectively). These differences could, in principle, be ex-
plained by increased homing. We therefore studied the
homing capacity of lineage-negative bone marrow cells in
lethally irradiated recipients and found reduced homing
of dKO bone marrow cells (Figure 3M). These data strongly
argue against increased homing as the explanation for the
significant expansion of dKO cells.
Taken together, the functional analyses demonstrate
that, LMPPs lacking STS1/STS2 exhibit a short-lived repo-
pulation advantage, whereas HSCs from dKO mice have a
remarkably enhanced capacity for long-term repopulation
after secondary transplantation. This indicates that loss of
STS1/STS2 endows both multipotent progenitors as well
as HSCs with increased cell fitness.
STS1 Dephosphorylates FLT3 and KIT
Given the phenotypic and functional changes identified in
dKO, we aimed to investigate the molecular mechanism
whereby STS1 and STS2 may affect MPP/LMPP expansion
and HSC maintenance. As depicted in Figure 1C, FLT3+
cells are strongly enriched in the bone marrow of dKO
mice. Since STS1 has been demonstrated to be a phospha-
tase of the EGF receptor, we asked whether FLT3
phosphorylation is altered by STS1 and/or STS2. First, we
determined that FLT3 and KIT bind to STS1 and STS2 in a
ligand-dependent manner in co-immunoprecipitation ex-
periments (Figures 4A and 4B). Because STS1 has been
shown to exhibit phosphatase activity through its PGM
domain, we analyzed the phosphorylation of FLT3uthors
Figure 2. Increased Colony-Forming Ability of STS1/STS2-Deficient Bone Marrow Cells In Vitro and In Vivo
(A) Colony numbers formed in methylcellulose containing IL3, IL6, SCF, and EPO (Methocult 3434). Bone marrow cells were pooled from
five dKO and five WT mice. Colonies were replated serially five times, each time in triplicate. Data represent mean ± SEM. ***p < 0.001.
(B) Morphological assessment of colonies from (A) as percentage of total colonies.
(C) Colony numbers formed by 500 sorted LSK cells from WT (white bar), dKO (black bar), and STS1KO (dark gray) mice. Data represent mean
± SEM of triplicate experiments. *p < 0.01.
(D) Cell numbers per colony were calculated from the experiment shown in (C). Data represent mean ± SEM.
(E) Morphological assessment of colonies from (C) as percentage of total colonies. Data represent mean ± SEM.
(F) Cells from colonies formed by LSK cells (as in B and C) were stained with the surface markers KIT, CD48, CD16/32, and MAC-1, followed
by FACS analysis.
(G) Colony-forming units of spleen (CFU-S12) at 12 days post-transplantation of 1 3 10e5 bone marrow cells into lethally irradiated
recipient mice (n = 5 in WT, n = 6 in dKO, n = 4 in WT+AC220, and n = 5 in dKO + AC220). Mice were treated daily by oral gavage with vehicle
or AC220. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).(Figure 4C) and KIT (Figure 4D) in the presence of overex-
pressed STS1 and STS2 or their phosphatase-defective mu-
tants (PGM*) (Mikhailik et al., 2007; Raguz et al., 2007).
As shown in Figures 4C and 4D, overexpression of STS1,Stem Cellbut not STS2, led to a reduction of ligand-induced phos-
phorylation of both FLT3 and KIT. This was dependent
on the functional phosphatase domain (PGM) of STS1
because no difference was observedwith PGM*. In a reverseReports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors 637
Figure 3. Enhanced Long-Term Repopulation Capacity of dKO HSCs
(A) Schematic of the competitive repopulation assays. Total bone marrow cells or sorted LSK cells from WT or dKO mice (CD45.2+) were
mixed with competitor WT bone marrow cells (CD45.1+). Mixed cells were transplanted intravenously into lethally irradiated (11 Gy)
congenic (CD45.1+) recipients (n = 10/group).
(B) Long-term repopulation assay using total bone marrow cells as the donor. Recipient mice (n = 10/group) were transplanted with 23
10e6 total bone marrow cells from five WT (white bar) or dKO (black bar) donors (CD45.2+) mixed with the same number of WT bone marrow
cells as competitors (CD45.1+). Data were obtained every 4 weeks (W) by analyzing peripheral blood for CD45.2+ donor cells.
(C) Repopulation assay using sorted LSKCD150CD48+ cells as the donor. Recipient mice (n = 6/group) were transplanted with 3,000 sorted
LSKCD150CD48+ cells from four WT (white bar) or dKO (black bar) mice (CD45.2+) mixed with 23 10e5 mononuclear bone marrow cells as
supporters (CD45.1+). Data were obtained every 4 weeks by analyzing peripheral blood for CD45.2+ donor cells.
(D) Percentage of differentiated cells in the peripheral blood 4 weeks after transplantation.
(E) Repopulation assay using sorted LSK cells as the donor. Recipient mice (n = 10/group) were transplanted with 3,000 sorted LSK cells
from five WT (white bar) or dKO (black bar) donors (CD45.2+) mixed with 2 3 10e5 mononuclear WT bone marrow cells as competitors
(CD45.1+). Data were obtained every 4 weeks by analyzing peripheral blood for CD45.2+ donor cells.
(F) Percentage of differentiated cells in the peripheral blood 8 weeks after transplantation.
(legend continued on next page)
638 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors
approach, we made use of short hairpin RNA (shRNA)
constructs of STS1 and determined a constitutive,
ligand-independent phosphorylation (i.e., activation) of
FLT3 as well as a hyperphosphorylation of FLT3 in
response to FLT3 ligand (FL) stimulation (Figure 4E; Fig-
ure S4). As a consequence, this led to consecutive hyper-
activation of AKT (Figure 4E). Furthermore, an enhanced
FL-dependent expansion was induced by STS1 knock-
down in an FLT3-expressing 32D myeloid cell line. This
was prevented by the application of a specific FLT3 inhib-
itor, AC220 (Taylor et al., 2012; Zarrinkar et al., 2009),
demonstrating that cell growth depends on FLT3 kinase
activity (Figure 4F).Hyperphosphorylation of FLT3 in dKO Mice Results
in a Proliferative Advantage of LSK Cells
Next we aimed to monitor the phosphorylation and
signaling events in our genetic mouse model. Lin bone
marrow cells were used for intracellular staining with
p-FLT3 antibody. Interestingly, dKO cells showed a signifi-
cantly higher p-FLT3 signal compared with the WT in the
absence of FL stimulation in Lin, LSK, and LinKIT+
SCA (LKSCA) cell populations (Figure 5A, top), suggest-
ing constitutive FLT3 activation. This was also observed
in STS1KO and, to a lesser extent, in STS2KO cells (Fig-
ure S5A). This difference was abolished by the addition of
FL, leading to equal p-FLT3 signals of WT, dKO, and single
KO cells (Figure 5A; Figure S5A, bottom). Analysis of the
downstream signaling events in Lin bonemarrow cells re-
vealed a higher AKT phosphorylation in dKO and STS1KO
mice compared with the WT (Figure 5B).
We then asked whether the constitutive activation of
FLT3 in dKO is responsible for the LSK expansion (Figure 1).
When purified LSK cells were cultured ex vivo in the pres-
ence of SCF and TPO, we observed a faster cell proliferation
of dKOLSK cells comparedwith theWT (Figure 5C, straight
line).However, the effectwas reversed upon FL stimulation,
with an identical expansion curve between the analyzed ge-
notypes (Figure 5C, dotted line). Application of the FLT3 in-(G) Total bone marrow cells from first-transplantation hosts (shown in
surface markers. The donor LSK, LSKCD34+, and LSKCD34 cell freque
(H) Total bone marrow cells were isolated from first-transplantation
recipients. For each transplantation, 53 10e5 bone marrow cells from
were transplanted. Data were obtained every 4 weeks by analyzing pe
(I) Percentage of differentiated cells in the peripheral blood 8 weeks
(J) Total bone marrow cells from the second transplantation (shown i
donor cell percentage in Lin, LSK, LinKIT+SCA compartments is s
(K) Engraftment of WT or dKO LSK donor cells (CD45.2+) in primary a
(L) Engraftment of WT or dKO LSK c donor cells (CD45.2+) in primary
(M) Homing of WT and dKO Lin donor cells in recipients’ bone marrow
transplanted into lethally irradiated recipient mice. These mice were s
analysis.
*p < 0.05, **p < 0.01, ***p < 0.001. Data represent the mean ± SEM
Stem CellhibitorAC220 reduced cell expansion to the same level (Fig-
ure 5C, dashed line). No block in differentiation was
determined under these conditions (Figures S5B–S5E).
To further confirm the effect of STS1 and STS2 on cell pro-
liferation, LSKCD48 cells were labeled with a cell prolifer-
ation tracker, which allows FACS tracing overmultiple gen-
erations by measuring the dye dilution. Labeled dKO cells
showed an accelerated dilution of the proliferation tracker
in the presence of SCF and TPO (i.e., faster cell division)
compared with the WT (Figure 5D, left). However, when
FL or AC220 were added, the dilution of the fluorescent
dye was similar in dKO and WT cells (Figure 5D, center
and right), suggesting that the growth advantage of dKO
cells is at least partially caused by FLT3 kinase activity.
In summary, these data indicate that depletion of STS1/
STS2 causes a constitutive phosphorylation of FLT3 andhy-
peractivation of downstream AKT signaling, which results
in elevated ex vivo LSK cell expansion.Accelerated Recovery of Hematopoietic Stem and
Progenitor Cells in STS1/STS2-Deficient Mice after
Cytotoxic Stress In Vivo
We asked whether the enlarged LSK population in dKO
mice is due to increased proliferation in vivo. Bromodeox-
yuridine (BrdU) incorporation was analyzed in different
compartments, but no significant changes were observed
(Figure 6A). Next we assessed the quiescence status by
Ki67 staining because Ki67 is a nuclear protein expressed
in active cycling cells (G1/S/G2/M) and absent in resting
cells (G0). No difference was evident under homeostatic
conditions (Figure 6B). Apoptosis in distinct bone marrow
compartments showed no differences between genotypes
(Figure 6C). We then challenged hematopoiesis by a single
5-fluorouracil (5-FU) injection, which causes cytotoxicity
to all actively cycling cells, resulting in ablation of the
proliferating progenitor pool and sparing only quiescent
(stem) cells (Venezia et al., 2004; Wilson et al., 2008,
2009). Analyses of the bone marrow composition after
5-FU injection indicate that there is a continuous increaseD) were isolated (fromWT, n = 5; from dKO, n = 6) and stained for cell
ncy in total bone marrow is shown for each mouse.
hosts (shown in D and E) and retransplanted into secondary (2)
the primary hosts plus an equal number of supporter cells (CD45.1)
ripheral blood for CD45.2+ donor cells (n = 10/group).
after transplantation.
n F, n = 5/group) were isolated and stained for surface markers. The
hown for each mouse.
nd secondary recipients in the spleen (SP) (n = 10/group).
and secondary recipients in BM (n = 10/group).
(n = 4/group). Lineage-negative bone marrow cells were labeled and
acrificed after 16 hr to isolate their bone marrow, followed by FACS
. See also Figure S3.
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Figure 4. STS1/STS2 Interact with FLT3/
KIT and Function as Phosphatases
(A) 293T cells were transiently transfected
with FLT3 and FLAG-tagged STS1 or STS2
constructs. Cells were serum-starved over-
night and then stimulated for 10 min at
37C with 40 ng/ml FL. FLT3 was immuno-
precipitated, and co-IP of STS1/STS2 was
detected by immunoblotting. IP, immuno-
precipitation; iso, normal rabbit antibody;
Ab, antibody.
(B) 293T cells were co-transfected with KIT
and FLAG-tagged STS1 or STS2 constructs.
Cells were serum-starved and stimulated
with KIT ligand (SCF 40 ng/ml) for 10 min.
KIT was immunoprecipitated and co-IP of
STS1/STS2was detected by immunoblotting.
(C) Phosphatase activity of STS proteins on
FLT3 was analyzed by co-expression of FLT3
and the respective STS constructs. FLT3 and
FLAG-tagged STS1/STS2 or their PGM domain
point mutants STS1* and STS2* were tran-
siently transfected into 293T cells. Cells were
serum-starved and stimulated with FL
(40 ng/ml) for 10 min. FLT3 was immuno-
precipitated and detected with anti-FLT3
and pan-pY antibody (4G10).
(D) Phosphatase activity of STS proteins on
KITwas analyzed by co-expression of KIT and
the respective STS constructs. Cells were
serum-starved and stimulated with SCF
(40 ng/ml) for 10 min. KIT was immunopre-
cipitated. Total KIT and pan-pY were de-
tected by immunoblotting.
(E) 32D cells stably expressing FLT3WT were transfected with shRNA against STS1 (Seq1 and Seq2) or a non-specific sequence (nsp) and
stimulatedwith FL (100 ng/ml) for different times after serum and cytokine starvation. FLT3 phosphorylation and downstream signalingwere
detected by western blot.
(F) The influence of STS1 knockdown on 32D-FLT3WT cell growth was measured by 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide (XTT) assay. XTT absorptionwasmeasured after 48 hr in the absence (FL 0) or presence of FLT3 ligand: 10 ng/ml (FL10)
and 100 ng/ml (FL100) with or without the kinase inhibitor AC220 (20 nM) (+AC).
Data are mean ± SEM (n = 3 experiments). See also Figure S4.of the stem and progenitor populations and Ki67+ cells
from days 3–7, indicating a gradual recovery of these pop-
ulations (Figures S6A and S6B). By analyzing the cell-cycle
status by Ki67 and 7-aminoactinomycin D (7AAD) stain-
ing, dKO mice show a larger population of proliferating
cells (S/G2/M) and fewer quiescent cells (in G0 phase)
within both the LSK and HSC (LSK CD150+CD48) com-
partments on day 6 after 5-FU injection (Figures 6D and
6E). These data suggest that dKO bone marrow cells exit
G0 and divide faster after 5-FU-induced myeloablation
(Figures 6D and 6E). Consistently, STS1/STS2-deficient
mice showed an improved recovery in white blood cells
(WBCs) compared with the WT (day 7 onward; Figure 6F).640 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The AMore cells were produced by dKO when equal bone
marrow cells from day 8 after single 5FU injection were
seeded for colony assays (Figure 6G, right). In a detailed im-
munophenotype analysis, mice lacking STS1/STS2 also
demonstrated enhanced recovery of LSK populations on
day 8, which was especially prominent in the LSKCD48+
compartment (Figure 6H), although both the dKO and
WT groups showed a similar loss of KIT+ cells on day 2
(Figure S6C).
In summary, the data demonstrate that, after 5-FU cyto-
toxic injury, the quiescent HSCs from dKO mice cycle
and proliferate faster and show enhanced recovery
compared with their WT controls.uthors
Figure 5. Hyperphosphorylation of FLT3
and Faster Ex Vivo Proliferation of dKO
LSK
(A) Intracellular staining of pY591-FLT3
with (FL 10’) or without (FL 0’) FLT3 ligand
stimulation in Lin bone marrow cells from
WT (red) and dKO (blue) mice. Cells were
gated on different compartments, and FLT3
phosphorylation on pY591 is shown. Data
are representative of three independent
experiments.
(B) Lin bone marrow cells were isolated
from WT and dKO mice and used for immu-
noblotting. Data are representative of four
independent experiments.
(C) LSK cells were sorted and ex vivo-
cultured in serum-free medium in the pres-
ence of different cytokines or the FLT3-in-
hibitor AC220. Data are representative of
four independent experiments.
(D) LSKCD48 cells were sorted, labeled with proliferation tracker violet, and cultured ex vivo in serum-free medium under the indicated
conditions. The dilution of the proliferation tracker was measured after 4 days. Data are representative of two independent experiments.
See also Figure S5.DISCUSSION
FLT3 and KIT are key RTKs controlling HSPCs. Ubiquitina-
tion and dephosphorylation are two important mecha-
nisms to negatively regulate RTK signaling (Dikic and
Giordano, 2003; Sastry and Elferink, 2011).
By using single- and double-knockout mice, our data
demonstrate that loss of both STS1/STS2 causes a remark-
able expansion of the MPP and LMPP cell populations.
Consistently, functional analyses demonstrated increased
colony-forming ability and a strong but transient engraft-
ment advantage after transplantation of sorted LMPPs, sug-
gesting enhanced multipotent progenitor cell fitness. Sur-
prisingly, although HSCs were not increased in number,
competitive repopulation assays demonstrated that dKO
mice display a dramatically elevated long-term repopula-
tion capacity after serial transplantation. Because the
LMPP transplantation did not provide evidence of long-
term repopulation capacity from these progenitor cells,
our data indicate that HSCs lacking STS1/STS2 have supe-
rior fitness and efficiently replenish the MPP and LMPP
pools. Of note, with increasing age, the LSK compartment
of dKOmice amplifies, which provides further circumstan-
tial evidence of improved HSC fitness.
The functional analyses demonstrated that increased
proliferation and increased cell fitness account for the
phenotype upon loss of STS1/STS2, whereas we found no
evidence of increased bone marrow homing, reduced
apoptosis, or blocked differentiation. Although we cannot
fully exclude non-cell autonomous effects, the signifi-
cantly increased hematopoietic stem and progenitor cellStem Cellexpansion of dKO cells after secondary transplantation
strongly argue in favor of a direct cell-autonomous effect
of STS1/STS2 loss on HSCs and multipotent progenitor
cells.
These data are in agreement with observations made in
CBL and Itch knockout mice, which show a significant
expansion of HSCs, MPPs, and LMPPs upon serial trans-
plantation and under stress conditions (Heidel et al.,
2013; Rathinam et al., 2008, 2011). Interestingly, our data
revealed that the increased LSK compartment in STS1/
STS2 dKO mice is mainly restricted to the expansion of
MPP and LMPP subpopulations, with no phenotypic
expansion of HSCs. The difference from CBL and Itch
knockout mice may be due to the fact that these E3 ligases
affect more signaling molecules and pathways (Schmidt
and Dikic, 2005), whereas STS1/STS2 may have more spe-
cific functions and binding partners.
At the molecular level, our data demonstrate that the
growth advantage of dKO HSPCs is largely dependent on
increased FLT3 kinase activity (with subsequent constitu-
tive AKT activation) and can be prevented by FLT3 inhibi-
tion. Consistently, a recent publication regarding FLT3
knockout mice has shown that FLT3 deficiency impaired
the expansion of multipotent progenitor cells, thereby
blocking the generation of both lymphoid and myeloid
progenitors (Beaudin et al., 2014).
Importantly, our findings suggest that STS1/STS2 func-
tion is important under stress conditions in HSPCs after
transplantation. On the contrary, under steady-state condi-
tions, the role of STS1/STS2 is dispensable. Similarly, the
effects of FLT3 deficiency on the generation of all matureReports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors 641
Figure 6. Accelerated Hematopoietic Recovery of dKO Mice after Cytotoxic Stress In Vivo
(A) BrdU incorporation in different bone marrow compartments at steady state (n = 5/group).
(B) Ki67+ cell percentage in different bone marrow compartments at steady state (WT, n = 5; dKO, n = 6).
(C) Percentage of apoptotic cells (as percent Annexin V+) in different bone marrow compartments (n = 5/group).
(D) Representative FACS plots of cell-cycle status based on Ki67 and 7AAD staining in LSK, LSKCD150+CD48, and LSKCD48+ compartments
on day 6 after 5-FU injection.
(E) Cell-cycle status on day 6 after a single 5-FU injection (as shown in D; WT, n = 4; dKO, n = 3).
(F) WBC counts on different days after a single 5-FU injection (WT, n = 4; dKO, n = 5).
(G) Colony numbers formed by 5,000 total bone marrow cells from WT/dKO mice 8 days after 5-FU injection (left). Also shown are cell
numbers per colony (right). Data are mean ± SEM (n = 3 experiments).
(H) Distribution of HSPC compartments in WT and dKO total BM (n = 7/group) on day 8 after a single 5-FU injection. Data represent
mean ± SEM.
See also Figure S6.lineages are only detectable after transplantation of puri-
fied progenitors (Beaudin et al., 2014). The constitutive
activation of FLT3 in our STS1/STS2 dKO model causes
neither HSC exhaustion nor leukemia development as in
the CBL or Itch KO model (Heidel et al., 2013; Rathinam
et al., 2008, 2011). On the contrary, previous reports of
work with the oncogenic mutant FLT3-ITD have found
defective HSC function (Adolfsson et al., 2001; Chu et al.,
2012). However, FLT3-ITD expression differs from WT-
FLT3 in many aspects, including strong activation of
STAT5 and a subcellular localization to the ER, which alters642 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Asignaling qualities and receptor trafficking (Choudhary
et al., 2007, 2009). Therefore, numerous biological proper-
ties of FLT3-ITD account for the difference to our dKO
phenotype.
As reported, FLT3 is mainly expressed on progenitor cells
inmice, and both FLT3 and its ligand FL are dispensable for
HSC maintenance and post-transplantation expansion
(Adolfsson et al., 2005; Boyer et al., 2011; Buza-Vidas et al.,
2009). In contrast, KIT plays an essential role in regulating
HSC self-renewal and cell quiescence (Sharma et al.,
2007; Thore´n et al., 2008). Interestingly, STS1 showeduthors
phosphatase activity on both FLT3 and KIT in vitro.
Although we only detected hyperphosphorylation of FLT3
(but not KIT) in primary dKO cells, we cannot exclude lim-
itations of reagents to detect phospho-KIT. Therefore, we
postulate that, in dKO mice, increased KIT activity may be
responsible for enhanced HSC fitness. Nevertheless, the
basal level of FLT3 expression (mRNA and intracellular pro-
tein) is also detectable in long-term engrafting SLAM cells
(Chu et al., 2012), suggesting a possible mechanism of
STS1/STS2 affecting HSC via FLT3. Furthermore, we cannot
exclude that STS1/STS2 may have additional phosphatase
substrates contributing to the hematological phenotype.
Interestingly, we observed increased cell-cycle entry and
faster cell-cycle progression after 5-FU injection in dKO
HSCs, indicating that STS1/STS2 might also be involved
in cell-cycle regulation. Because the cell cycle is tightly
controlled by the phosphorylation of several regulators
(Kalaszczynska et al., 2009; Pietras et al., 2011), it can be
speculated that some of these regulators may be STS1/
STS2 phosphatase substrates.
Importantly, STS1 and STS2 have been shown to have
overlapping functions (Carpino et al., 2002; Carpino
et al., 2004). However, although expansion of LSK,
increased serial colony growth, and hyperphosphorylation
of FLT3 were largely attributable to the loss of STS1, further
loss of STS2 strengthened the phenotype, and depletion of
STS2 showed in vivo phosphatase activity as well. Because
STS1 and STS2 differ in their substrate specificity (Chen
et al., 2009a, 2009b) and their expression pattern differs
in hematopoiesis, we suspect that subtle functional differ-
ence exist between STS1 and STS2.
Studies on several other phosphatases, such as SHP2,
PRL2, PTPs, and PTPz, indicate a frequent involvement
of phosphatases in HSC regulation. Among these, PTPs
and PTPz are transmembrane receptor tyrosine phospha-
tases. Knockout of these proteins augments HSC function.
However, their effects are non-autonomous and are rather
due to their interaction with the bone marrow microenvi-
ronment (Himburg et al., 2012; Quarmyne et al., 2015).
SHP2 and PRL2 are both intra-cytoplasmic phosphatases
and have been shown to increase HSC self-renewal as
opposed to STS1/STS2 (Chan et al., 2011; Kobayashi
et al., 2014; Zhu et al., 2011). None of the phosphatases
(SHP2, PRL2, PTPs, and PTPz) have been reported to
directly dephosphorylate RTKs.
In summary, we elucidated that (1) dKO mice display
phenotypic expansion and increased fitness of MPPs and
LMPPs; (2) HSCs lacking STS1/STS2 exhibit improved
fitness; and (3) STS1/STS2 are direct phosphatases of FLT3
and KIT. Our data imply that phosphatase inhibition of
STS1 and STS2 may potentially improve hematopoietic re-
covery after bone marrow transplantation, opening new
venues for therapeutic intervention.Stem CellEXPERIMENTAL PROCEDURES
Reagents and Antibodies
Recombinant human and murine cytokines were purchased from
PeproTech. Methylcellulose (MethoCult 3630, catalog no. 3434)
was purchased from STEMCELL Technologies. All antibody infor-
mation is summarized in Table S1.
Mice
STS1 and STS2 dKO mice have been reported previously and were
backcrossed for 10 generations onto the C57BL6 background (Car-
pino et al., 2002, 2004). The dKOmice were crossedwith wild-type
C57BL6 mice to generate STS1/ and STS2/ single-knockout
mice. All mice were kept under specific pathogen-free conditions
in the animal care facility. Mouse experiments were approved by
the local animal experimentation committee.
Cell Lines
The32Dcl3and293Tcell lineswere culturedasdescribedpreviously
(Bandi et al., 2009; Sargin et al., 2007). The stable 32D-FLT3 cell line
was generated by retroviral transduction with human FLT3WT. For
STS1 knockdown experiments, stable 32D-FLT3 cell lines were in-
fected lentivirally with pLKO.1-STS1-shRNA (sequences 1 and 2)
or non-specific shRNA (nsp) from Sigma Aldrich.
Flow Cytometry
Single-cell suspensions were measured on flow cytometers: FACS-
Fortessa or FACSCanto II (BD Biosciences). FACSDiva software
(BD Biosciences) or FlowJo software (Tree Star) were used for data
analyses. Cells were sorted into defined subpopulations with a
FACSAria II (BD Biosciences). Total or lineage-negative bone
marrow cells were stained and gated according to established
methods (Kiel et al., 2005; Oguro et al., 2013; Rathinam et al.,
2008, 2011; Yamamoto et al., 2013; Yilmaz et al., 2006). For the
CLP assay, total bone marrow cells were stained with a lineage
cocktail (CD3, CD11b, GR1, and TER119) and B220 with separate
fluorochromes (Karsunky et al., 2008). Isotype antibodies were
used as negative controls for FACS gating.
Homing Assay
Lineage-deprived WT or dKO bone marrow cells were labeled with
CellTrace carboxyfluorescein succinimidyl ester (CFSE) (Life Tech-
nologies), and5X10e5cellswere transplanted into lethally irradiated
recipients. 16 hr later, recipients were sacrificed, and the percentage
of CFSE+ cells in total bone marrow was analyzed by FACS.
Competitive Repopulation Assays and Bone Marrow
Transplantation Studies
For competitive repopulation experiments, total bone marrow,
sorted LSKCD150CD48+ cells, or LSK cells from wild-type or
dKO mice (CD45.2+) were mixed with competitor bone marrow
cells (CD45.1+). The mixed cells were transplanted intravenously
into lethally irradiated (11 Gy) congenic (CD45.1+) recipients.
Mice were bled every 4 weeks. The donor cell percentage and dis-
tribution of the myeloid or lymphoid populations were analyzed
by FACS.Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors 643
Colony-Forming Unit Assays
For colony-forming unit assays, 3 3 10e4 mononucleated bone
marrow cells or 500 sorted LSK cells were cultured in semisolid
methylcellulose (containing IL3, IL6, SCF, and EPO). Colonies
were scored according to the manufacturer’s instructions. Cells
were collected and replated several times.
For CFU-S assays, 100,000 mononucleated bone marrow cells
from WT or dKO mice were injected into lethally irradiated recip-
ient WT mice. The recipient mice were given vehicle or 10 mg/kg
AC220 (in 0.5%methycellulose) by oral gavage for 11 days (Taylor
et al., 2012). Mice were sacrificed on day 12, and colony numbers
were counted on the spleen surface.Treatment with BrdU or 5-FU
Mice were given a single intraperitoneal dose of BrdU (1 mg) or
5-FU (150 mg/kg body weight) and sacrificed at the indicated
times. Peripheral blood counts were measured by Hemavet.
ACCESSION NUMBERS
The accession numbers for the human STS1 and STS2 sequences
used for in vitro expression are GenBank: NM_032873.4,
NM_001001895.
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can be found with this article online at http://dx.doi.org/10.
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AUTHOR CONTRIBUTIONS
J.Z. andC.B. designed the research and analyzed the data. J.Z., O.V.,
S.R.B., O¨.D, J.U.K., R.G.F., K.J., and A.E. performed the experi-
ments. J.Z., L.R., N.C., M.R., H.S., and C.B. interpreted the results
and discussed the data. J.Z. and C.B. wrote the manuscript.
ACKNOWLEDGMENTS
We wish to thank Frank Bo¨hmer and Jo¨rg Mu¨ller for numerous
helpful experimental suggestions and careful reading of themanu-
script. We also thank Daniela Ho¨ller for reagents and initial plan-
ning of the experiments. The authors thankDeutsche Jose´ Carreras
Leuka¨mie-Stiftung (grant DJCLS F 10/03 to J.Z.), the German Can-
cer Aid (Deutsche Krebshilfe, 108688 and 108400, to C.H.B) and
LOEWE (IIIL4-518/17.004 [2010] and IIIL6-518/75.004 [2013], to
C.H.B.).
Received: January 28, 2015
Revised: August 5, 2015
Accepted: August 6, 2015
Published: September 10, 2015REFERENCES
Adolfsson, J., Borge, O.J., Bryder, D., Theilgaard-Mo¨nch, K., As-
trand-Grundstro¨m, I., Sitnicka, E., Sasaki, Y., and Jacobsen, S.E.
(2001). Upregulation of Flt3 expression within the bone marrow644 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The ALin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by
loss of self-renewal capacity. Immunity 15, 659–669.
Adolfsson, J., Ma˚nsson, R., Buza-Vidas, N., Hultquist, A., Liuba, K.,
Jensen, C.T., Bryder, D., Yang, L., Borge, O.J., Thoren, L.A., et al.
(2005). Identification of Flt3+ lympho-myeloid stem cells lacking
erythro-megakaryocytic potential a revised road map for adult
blood lineage commitment. Cell 121, 295–306.
Bandi, S.R., Brandts, C., Rensinghoff, M., Grundler, R., Ticken-
brock, L., Ko¨hler, G., Duyster, J., Berdel, W.E., Mu¨ller-Tidow, C.,
Serve, H., and Sargin, B.; Study Alliance Leukemias (2009). E3
ligase-defective Cbl mutants lead to a generalized mastocytosis
and myeloproliferative disease. Blood 114, 4197–4208.
Beaudin, A.E., Boyer, S.W., and Forsberg, E.C. (2014). Flk2/Flt3 pro-
motes both myeloid and lymphoid development by expanding
non-self-renewing multipotent hematopoietic progenitor cells.
Exp. Hematol. 42, 218–229.e4.
Boyer, S.W., Schroeder, A.V., Smith-Berdan, S., and Forsberg, E.C.
(2011). All hematopoietic cells develop from hematopoietic stem
cells through Flk2/Flt3-positive progenitor cells. Cell Stem Cell 9,
64–73.
Buza-Vidas, N., Cheng, M., Duarte, S., Charoudeh, H.N., Jacobsen,
S.E.W., and Sitnicka, E. (2009). FLT3 receptor and ligand are
dispensable for maintenance and posttransplantation expansion
of mouse hematopoietic stem cells. Blood 113, 3453–3460.
Carpino, N., Kobayashi, R., Zang, H., Takahashi, Y., Jou, S.-T., Feng,
J., Nakajima, H., and Ihle, J.N. (2002). Identification, cDNA clon-
ing, and targeted deletion of p70, a novel, ubiquitously expressed
SH3 domain-containing protein. Mol. Cell. Biol. 22, 7491–7500.
Carpino, N., Turner, S., Mekala, D., Takahashi, Y., Zang, H., Geiger,
T.L., Doherty, P., and Ihle, J.N. (2004). Regulation of ZAP-70 activa-
tion and TCR signaling by two related proteins, Sts-1 and Sts-2.
Immunity 20, 37–46.
Carpino, N., Chen, Y., Nassar, N., and Oh, H.-W. (2009). The Sts
proteins target tyrosine phosphorylated, ubiquitinated proteins
within TCR signaling pathways. Mol. Immunol. 46, 3224–3231.
Chan, G., Cheung, L.S., Yang, W., Milyavsky, M., Sanders, A.D.,
Gu, S., Hong, W.X., Liu, A.X., Wang, X., Barbara, M., et al.
(2011). Essential role for Ptpn11 in survival of hematopoietic
stem and progenitor cells. Blood 117, 4253–4261.
Chen, Y., Jakoncic, J., Carpino, N., and Nassar, N. (2009a). Struc-
tural and functional characterization of the 2H-phosphatase
domain of Sts-2 reveals an acid-dependent phosphatase activity.
Biochemistry 48, 1681–1690.
Chen, Y., Jakoncic, J., Parker, K.A., Carpino, N., and Nassar, N.
(2009b). Structures of the phosphorylated and VO(3)-bound 2H-
phosphatase domain of Sts-2. Biochemistry 48, 8129–8135.
Choudhary, C., Brandts, C., Schwable, J., Tickenbrock, L., Sargin,
B., Ueker, A., Bo¨hmer, F.D., Berdel, W.E., Mu¨ller-Tidow, C., and
Serve, H. (2007). Activation mechanisms of STAT5 by oncogenic
Flt3-ITD. Blood 110, 370–374.
Choudhary, C., Olsen, J.V., Brandts, C., Cox, J., Reddy, P.N.,
Bo¨hmer, F.D., Gerke, V., Schmidt-Arras, D.E., Berdel, W.E.,
Mu¨ller-Tidow, C., et al. (2009). Mislocalized activation of onco-
genic RTKs switches downstream signaling outcomes. Mol. Cell
36, 326–339.uthors
Chu, S.H., Heiser, D., Li, L., Kaplan, I., Collector,M., Huso,D., Shar-
kis, S.J., Civin, C., and Small, D. (2012). FLT3-ITD knockin impairs
hematopoietic stem cell quiescence/homeostasis, leading to
myeloproliferative neoplasm. Cell Stem Cell 11, 346–358.
Dikic, I., and Giordano, S. (2003). Negative receptor signalling.
Curr. Opin. Cell Biol. 15, 128–135.
Feshchenko, E.A., Smirnova, E.V., Swaminathan, G., Teckchan-
dani, A.M., Agrawal, R., Band, H., Zhang, X., Annan, R.S., Carr,
S.A., and Tsygankov, A.Y. (2004). TULA: an SH3- and UBA-contain-
ing protein that binds to c-Cbl and ubiquitin. Oncogene 23, 4690–
4706.
Heidel, F.H., Bullinger, L., Arreba-Tutusaus, P., Wang, Z., Gaebel, J.,
Hirt, C., Niederwieser, D., Lane, S.W., Do¨hner, K., Vasioukhin, V.,
et al. (2013). The cell fate determinant Llgl1 influences HSC fitness
and prognosis in AML. J. Exp. Med. 210, 15–22.
Himburg, H.A., Harris, J.R., Ito, T., Daher, P., Russell, J.L., Quar-
myne, M., Doan, P.L., Helms, K., Nakamura, M., Fixsen, E., et al.
(2012). Pleiotrophin regulates the retention and self-renewal of he-
matopoietic stem cells in the bone marrow vascular niche. Cell
Rep. 2, 964–975.
Hoeller, D., Crosetto, N., Blagoev, B., Raiborg, C., Tikkanen, R.,
Wagner, S., Kowanetz, K., Breitling, R., Mann, M., Stenmark, H.,
and Dikic, I. (2006). Regulation of ubiquitin-binding proteins by
monoubiquitination. Nat. Cell Biol. 8, 163–169.
Kalaszczynska, I., Geng, Y., Iino, T., Mizuno, S., Choi, Y., Kondra-
tiuk, I., Silver, D.P., Wolgemuth, D.J., Akashi, K., and Sicinski, P.
(2009). Cyclin A is redundant in fibroblasts but essential in he-
matopoietic and embryonic stem cells. Cell 138, 352–365.
Karsunky, H., Inlay, M.A., Serwold, T., Bhattacharya, D., andWeiss-
man, I.L. (2008). Flk2+ common lymphoid progenitors possess
equivalent differentiation potential for the B and T lineages. Blood
111, 5562–5570.
Kiel,M.J., Yilmaz,O.H., Iwashita, T., Yilmaz,O.H., Terhorst, C., and
Morrison, S.J. (2005). SLAM family receptors distinguish hemato-
poietic stem and progenitor cells and reveal endothelial niches
for stem cells. Cell 121, 1109–1121.
Kobayashi,M., Bai, Y., Dong, Y., Yu, H., Chen, S., Gao, R., Zhang, L.,
Yoder, M.C., Kapur, R., Zhang, Z.Y., and Liu, Y. (2014). PRL2/
PTP4A2 phosphatase is important for hematopoietic stem cell
self-renewal. Stem Cells 32, 1956–1967.
Kowanetz, K., Crosetto, N., Haglund, K., Schmidt, M.H.H., Heldin,
C.-H., and Dikic, I. (2004). Suppressors of T-cell receptor signaling
Sts-1 and Sts-2 bind toCbl and inhibit endocytosis of receptor tyro-
sine kinases. J. Biol. Chem. 279, 32786–32795.
Mackarehtschian, K., Hardin, J.D., Moore, K.A., Boast, S., Goff, S.P.,
and Lemischka, I.R. (1995). Targeted disruption of the flk2/flt3
gene leads to deficiencies in primitive hematopoietic progenitors.
Immunity 3, 147–161.
Mikhailik, A., Ford, B., Keller, J., Chen, Y., Nassar, N., and Carpino,
N. (2007). A phosphatase activity of Sts-1 contributes to the sup-
pression of TCR signaling. Mol. Cell 27, 486–497.
Oguro, H., Ding, L., and Morrison, S.J. (2013). SLAM family
markers resolve functionally distinct subpopulations of hemato-
poietic stem cells and multipotent progenitors. Cell Stem Cell
13, 102–116.Stem CellPietras, E.M.,Warr, M.R., and Passegue´, E. (2011). Cell cycle regula-
tion in hematopoietic stem cells. J. Cell Biol. 195, 709–720.
Quarmyne, M., Doan, P.L., Himburg, H.A., Yan, X., Nakamura, M.,
Zhao, L., Chao, N.J., and Chute, J.P. (2015). Protein tyrosine phos-
phatase-s regulates hematopoietic stem cell-repopulating capac-
ity. J. Clin. Invest. 125, 177–182.
Raguz, J., Wagner, S., Dikic, I., andHoeller, D. (2007). Suppressor of
T-cell receptor signalling 1 and 2 differentially regulate endocytosis
and signalling of receptor tyrosine kinases. FEBS Lett. 581, 4767–
4772.
Rathinam, C., Thien, C.B.F., Langdon, W.Y., Gu, H., and Flavell,
R.A. (2008). The E3 ubiquitin ligase c-Cbl restricts development
and functions of hematopoietic stem cells. Genes Dev. 22,
992–997.
Rathinam, C., Thien, C.B., Flavell, R.A., and Langdon,W.Y. (2010).
Myeloid leukemia development in c-Cbl RING finger mutant mice
is dependent on FLT3 signaling. Cancer Cell 18, 341–352.
Rathinam, C., Matesic, L.E., and Flavell, R.A. (2011). The E3 ligase
Itch is a negative regulator of the homeostasis and function of he-
matopoietic stem cells. Nat. Immunol. 12, 399–407.
Rossi, L., Lin, K.K., Boles, N.C., Yang, L., King, K.Y., Jeong, M.,
Mayle, A., and Goodell, M.A. (2012). Less is more: unveiling the
functional core of hematopoietic stem cells through knockout
mice. Cell Stem Cell 11, 302–317.
Ryan, P.E., Davies, G.C., Nau, M.M., and Lipkowitz, S. (2006).
Regulating the regulator: negative regulation of Cbl ubiquitin li-
gases. Trends Biochem. Sci. 31, 79–88.
Sargin, B., Choudhary, C., Crosetto, N., Schmidt, M.H., Grundler,
R., Rensinghoff, M., Thiessen, C., Tickenbrock, L., Schwa¨ble, J.,
Brandts, C., et al. (2007). Flt3-dependent transformation by inacti-
vating c-Cbl mutations in AML. Blood 110, 1004–1012.
Sastry, S.K., and Elferink, L.A. (2011). Checks and balances: inter-
play of RTKs and PTPs in cancer progression. Biochem. Pharmacol.
82, 435–440.
Schmidt, M.H.H., and Dikic, I. (2005). The Cbl interactome and its
functions. Nat. Rev. Mol. Cell Biol. 6, 907–918.
Sharma, Y., Astle, C.M., and Harrison, D.E. (2007). Heterozygous
kit mutants with little or no apparent anemia exhibit large defects
in overall hematopoietic stem cell function. Exp. Hematol. 35,
214–220.
Taylor, S.J., Dagger, S.A., Thien, C.B., Wikstrom, M.E., and Lang-
don, W.Y. (2012). Flt3 inhibitor AC220 is a potent therapy in a
mouse model of myeloproliferative disease driven by enhanced
wild-type Flt3 signaling. Blood 120, 4049–4057.
Thore´n, L.A., Liuba, K., Bryder, D., Nygren, J.M., Jensen, C.T., Qian,
H., Antonchuk, J., and Jacobsen, S.E. (2008). Kit regulates mainte-
nance of quiescent hematopoietic stem cells. J. Immunol. 180,
2045–2053.
Toffalini, F., and Demoulin, J.-B. (2010). New insights into the
mechanisms of hematopoietic cell transformation by activated re-
ceptor tyrosine kinases. Blood 116, 2429–2437.
Venezia, T.A., Merchant, A.A., Ramos, C.A., Whitehouse, N.L.,
Young, A.S., Shaw, C.A., and Goodell, M.A. (2004). Molecular sig-
natures of proliferation and quiescence in hematopoietic stem
cells. PLoS Biol. 2, e301.Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Authors 645
Verstraete, K., and Savvides, S.N. (2012). Extracellular assembly
and activation principles of oncogenic class III receptor tyrosine ki-
nases. Nat. Rev. Cancer 12, 753–766.
Wilson, A., Laurenti, E., Oser, G., van der Wath, R.C., Blanco-Bose,
W., Jaworski,M., Offner, S., Dunant, C.F., Eshkind, L., Bockamp, E.,
et al. (2008). Hematopoietic stem cells reversibly switch from
dormancy to self-renewal during homeostasis and repair. Cell
135, 1118–1129.
Wilson, A., Laurenti, E., and Trumpp, A. (2009). Balancing
dormant and self-renewing hematopoietic stem cells. Curr. Opin.
Genet. Dev. 19, 461–468.
Yamamoto, R., Morita, Y., Ooehara, J., Hamanaka, S., Onodera,
M., Rudolph, K.L., Ema, H., and Nakauchi, H. (2013). Clonal
analysis unveils self-renewing lineage-restricted progenitors646 Stem Cell Reports j Vol. 5 j 633–646 j October 13, 2015 j ª2015 The Agenerated directly from hematopoietic stem cells. Cell 154,
1112–1126.
Yilmaz, O.H., Kiel, M.J., and Morrison, S.J. (2006). SLAM family
markers are conserved among hematopoietic stem cells from old
and reconstituted mice and markedly increase their purity. Blood
107, 924–930.
Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., Gardner, M.F.,
Brigham, D., Belli, B., Karaman, M.W., Pratz, K.W., Pallares, G.,
Chao, Q., et al. (2009). AC220 is a uniquely potent and selective in-
hibitor of FLT3 for the treatment of acutemyeloid leukemia (AML).
Blood 114, 2984–2992.
Zhu, H.H., Ji, K., Alderson, N., He, Z., Li, S., Liu,W., Zhang, D.E., Li,
L., and Feng, G.S. (2011). Kit-Shp2-Kit signaling acts to maintain a
functional hematopoietic stem and progenitor cell pool. Blood
117, 5350–5361.uthors
